On 17 October 2017, Ablynx launched an IPO of new shares in the form of American Depositary Shares ("ADSs") in the United States.

Ablynx raised USD 230 million in the IPO and was listed on the Nasdaq Global Select Market.

Ablynx is a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need.

Eubelius has acted as counsel to Ablynx since inception in 2001 and is proud to have assisted the company with its successful Nasdaq IPO. The team members involved in this transaction were Lars Van Bever, Robin Van Gysel and Eva Milants.